2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1690

Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1586

Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1329

Efficacy and Safety of Biologics in Relapsing Polychondritis: A National Multicenter Study in France

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1635

Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1632

Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1591

Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1364

Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1343

Efficacy of Biological-Targeted Treatments in MDS-Related Systemic Autoimmune Diseases: Multicenter Retrospective Study of 28 Patients

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1896

Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1736

Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1609

Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1117

EGCG Down-Regulates TNF-α-Induced Mcl-1 Expression By Modulating Mule/Huwe1, β-TrCP, and USP9X Ubiquitin/De-Ubiquitin Ligases in Rheumatoid Arthritis Synovial Fibroblasts

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1483

Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1904

Elevated GITRL Is Associated with Multi-Organ Involvement and Increased Disease Activity of Primarty Sjogren’s Syndrome and Promotes Pathogenic Th1/17 Differentiation

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

9:00AM-11:00AM: Abstract Number: 1839

Elevated Plasma Cell-Free Mitochondrial DNA Defines a Subgroup of Lupus Patients with Membranous Lupus Nephritis

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].